Advance your academic career, collaborate globally, and expand your network—
join now
!
Dr. Zhijie Xu is an associate professor at Xiangya Hospital, Central South University, and also a visiting researcher at the Mayo Clinic in Minnesota, USA. He received his Medical Degree (2006-2011) at Xiangya School of Medicine, Central South University, and then received research training and was awarded his Doctoral Degree (2011-2016) from the Cancer Research Institute, Central South University. He has published over 110 research papers in prestigious journals, including Molecular Cancer (IF = 27.401), Nucleic Acids Res. (IF = 16.971), Journal of Hematology and Oncology (IF = 17.388), Journal of Thoracic Oncology (IF=13.357), Clinical and Translational Medicine (IF=11.492), Acta Pharmaceutica Sinica B (IF = 11.413). Presently, he is the Associate Editor for BMC Pulmonary Medicine, Frontiers in Pharmacology, and Technology in Cancer Research and Treatment. Dr. Zhijie Xu's research mainly focuses on cancer research and treatment, with the ultimate goal of translating mechanistic insights gained for new therapeutic modalities.
Dr. Zhijie Xu is an associate professor at Xiangya Hospital, Central South University, and also a visiting researcher at the Mayo Clinic in Minnesota, USA. He received his Medical Degree (2006-2011) at Xiangya School of Medicine, Central South University, and then received research training and was awarded his Doctoral Degree (2011-2016) from the Cancer Research Institute, Central South University. He has published over 110 research papers in prestigious journals, including Molecular Cancer (IF = 27.401), Nucleic Acids Res. (IF = 16.971), Journal of Hematology and Oncology (IF = 17.388), Journal of Thoracic Oncology (IF=13.357), Clinical and Translational Medicine (IF=11.492), Acta Pharmaceutica Sinica B (IF = 11.413). Presently, he is the Associate Editor for BMC Pulmonary Medicine, Frontiers in Pharmacology, and Technology in Cancer Research and Treatment. Dr. Zhijie Xu's research mainly focuses on cancer research and treatment, with the ultimate goal of translating mechanistic insights gained for new therapeutic modalities.
The user has no Co-authors.
You can be the first follower.